Answers are grounded in this paper and cite their sources.
Case report shows benefits of zanubrutinib therapy in a patient with Waldenström-associated CANDA.
To the best of our knowledge, this is the first patient with Waldenström-associated CANDA with clinical, hematological, and neurophysiological benefit after zanubrutinib therapy.
No takes yet. Share an insight, caveat, or question.
Tierro et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: